Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVI BioPharma Q2 Revenues Decline To $2.9m
AVI BioPharma has reported a revenue of $2.9m for the second quarter of 2009, a decrease when compared to $5.0m in the prior-year period. The company has reported
AVI BioPharma has reported a revenue of $2.9m for the second quarter of 2009, a decrease when compared to $5.0m in the prior-year period. The company has reported
Ikaria has acquired the exclusive worldwide license to Fibrex Medical’s portfolio of investigational compounds, for a range of critical care conditions. The investigational compounds – FX06, FX201, and
Millipore has acquired Oxford, UK-based BioAnaLab. The transaction enables Millipore to expand its biopharmaceutical services business into Europe and strengthen its position in the biopharmaceutical industry. The services
Array BioPharma (Array) has reported positive top-line data from a phase 1 clinical trial of its novel small molecule glucokinase activator (GKA) – ARRY-403. The drug met its
US Patent and Trademark Office (PTO) has issued US Patent Number 7,569,551 entitled Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides, on the method of using OncoGenex’s OGX-011,
PTC Therapeutics (PTC) has received a research milestone of $2m in its collaboration with Schering-Plough. The payment is in connection with the designation of a development candidate for
Seattle Genetics has received a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial
Cardiome and its co-development partner Astellas have reported that Astellas will undertake a single confirmatory additional phase 3 clinical trial of KYNAPID (vernakalant hydrochloride) Injection, for rapid conversion
EMD Serono and the University of Texas M D Anderson Cancer Center have signed a three years strategic alliance. The deal is to provide M D Anderson with
Daiichi Sankyo has reported the top line results from a phase III study of the anti-influenza virus agent, CS-8958. The study, named MARVEL (Multinational Asian Clinical Research for